What are the evidence‑based treatment options for insomnia, including behavioral interventions and first‑ and second‑line pharmacologic therapies?

Treatment for Insomnia

All adults with chronic insomnia should receive cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, and pharmacological therapy should only be added short-term if CBT-I fails, using shared decision-making to discuss benefits, harms, and costs. 1

First-Line Treatment: CBT-I

CBT-I is the gold standard initial treatment for chronic insomnia disorder with a strong recommendation based on moderate-quality evidence 1. This represents the most definitive recommendation in insomnia management.

What CBT-I Includes:

• Cognitive therapy addressing sleep-related thoughts and beliefs
• Behavioral interventions: sleep restriction and stimulus control
• Educational components: sleep hygiene instruction

Delivery Methods (All Effective):

• In-person individual or group therapy
• Telephone-based modules
• Web-based/digital platforms
• Self-help books

CBT-I can be performed in primary care settings 1 and improves multiple outcomes:

• Reduced sleep onset latency and wake after sleep onset
• Improved sleep efficiency and quality
• Increased remission rates and treatment response
• Reduced insomnia severity scores (ISI, PSQI)

Critical advantage: Harms from behavioral interventions are likely mild, unlike pharmacological options which carry significant risks 1.

Second-Line Treatment: Pharmacotherapy

Only consider medications after CBT-I has failed (weak recommendation, low-quality evidence) 1. This requires shared decision-making discussing benefits, harms, and costs, with emphasis on short-term use only (≤4 weeks for most agents) 1.

Medications with Evidence for Efficacy:

Nonbenzodiazepine hypnotics (Z-drugs):

• Eszopiclone and zolpidem: Improved global and sleep outcomes (low-to-moderate quality evidence) 1
• Effect sizes are small in absolute terms 2

Orexin receptor antagonists:

• Suvorexant: Improved treatment response and sleep outcomes (moderate-quality evidence) 1
• Daridorexant: Can be used for up to 3 months or longer in some cases 3

Antidepressants:

• Low-dose doxepin: Improved sleep outcomes including sleep onset latency, total sleep time, and wake after sleep onset (low-to-moderate quality evidence) 1
• Particularly relevant for older adults 4

Melatonergic agents:

• Prolonged-release melatonin 2mg: For patients ≥55 years, up to 3 months 3
• Ramelteon: Insufficient evidence in general population; some benefit in older adults for sleep onset latency 1

Benzodiazepines:

• Short-to-medium acting agents can be used short-term (≤4 weeks) 3
• Higher risk profile, especially in older adults

Medications NOT Recommended:

• Antihistamines (e.g., diphenhydramine)
• Antipsychotics
• Fast-release melatonin
• Phytotherapeutics (herbal remedies) 3, 5

Critical Safety Considerations

FDA Warnings Apply to Most Hypnotics:

• Cognitive and behavioral changes including driving impairment and motor vehicle accidents
• Risk of "sleep driving" and other complex sleep behaviors
• Behavioral abnormalities and worsening depression
• Lower doses recommended for women and older/debilitated adults 1

Observational Study Findings (Serious Harms):

Despite limited RCT harm data, observational studies demonstrate associations with:

• Dementia
• Fractures and serious injuries
• Major injury 1, 2

Common pitfall: Many patients continue hypnotics long-term despite FDA approval only for short-term use (4-5 weeks) and insufficient evidence for long-term benefit-harm balance 1.

Special Population: Older Adults

Older adults require particular caution:

• More likely to experience wake after sleep onset than sleep onset problems 1
• Preferred pharmacological options: low-dose doxepin, melatonin, ramelteon, dual orexin receptor antagonists 4
• Avoid or use extreme caution: benzodiazepines and Z-drugs due to fall risk, cognitive impairment, and fracture risk
• CBT-I remains first-line with demonstrated efficacy (low-to-moderate quality evidence) 1

Treatment Algorithm

1. Diagnose chronic insomnia: Symptoms ≥3 nights/week for ≥3 months causing clinically significant distress/impairment 1

2. Initiate CBT-I (any delivery method based on availability and patient preference)

3. If CBT-I insufficient after adequate trial:

   • Engage in shared decision-making about adding pharmacotherapy
   • Discuss specific risks: cognitive changes, falls, driving impairment, potential for dependence
   • Emphasize short-term use (4 weeks)
   • Consider patient age, comorbidities, and medication-specific profiles

4. Select medication based on:

   • General adults: Eszopiclone, zolpidem, suvorexant, or daridorexant
   • Older adults (≥55-65 years): Low-dose doxepin, prolonged-release melatonin, ramelteon, or orexin antagonists
   • Sleep onset vs. maintenance problems: Tailor selection accordingly

5. Plan for discontinuation from the start, using gradual taper (10-25% dose reduction weekly for benzodiazepines/Z-drugs) 6

Evidence gap: Comparative effectiveness between medication classes and versus behavioral therapy remains insufficient 2. When evidence is equivocal, prioritize CBT-I and medications with better safety profiles (orexin antagonists, low-dose doxepin, melatonin in appropriate age groups).